Despite lower revenue, Zumiez's P/S ratio aligns with the industry, hinting at overlooked limited growth expectations. The weaker revenue outlook could lead to a share price and P/S ratio drop. A positive shift is needed to justify the current P/S ratio.
The company's CEO, Rick Brooks, stated that they are reviewing cost-saving strategies which could include closing underperforming stores and reducing labor costs. Despite the downbeat outlook, the company expects to open 10 new stores.
The three-year loss experienced by shareholders may indicate unresolved business challenges. This long-term share price weakness is generally considered a bad sign. However, some contrarian investors might research the stock in hope of a turnaround.
Ark Invest buys more Coinbase shares amid SEC crackdown Cathie Wood's Ark Invest boosted its holdings in$コインベース(COIN.US)$amidst a crypto industry crackdown by the SEC, driving the stock to nearly five-month lows. Data from Cathie's Ark revealed that three of Wood's funds purchased over 400,000 Coinbase shares, with her main$ARK Innovation ETF(ARKK.US)$acquiring more than 300,000. This occurred as Coinbase's stock pri...
Gapping up $ドキュサイン(DOCU.US)$+16% (fiscal second-quarter earnings and revenue that topped Wall Street estimates and raised its forecast for fiscal-year billings.) $ゼットスケーラー(ZS.US)$+15% (the internet security platform issued a forecast better than Wall Street estimates.) $テスラ(TSLA.US)$+1.3% (The electric vehicle maker is considering building a lithium refinery for EV battery production in Texas this year, according to an applicati...
$ズミーズ(ZUMZ.US)$Even after accounting for negative growth for the next 5 years, and lower margins, on my most conservative estimates this stock should be at least 2x in the coming years.
Gainers: •$オクタ(OKTA.US)$+15.8% (In reaction to earnings) •$ストーン(STNE.US)$+12.9% (In reaction to earnings) •$ターニング・ポイント・セラピューティクス(TPTX.US)$+116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025) •$アミリックス・ファーマシューティカルズ(AMLX.US)$+24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
$ズミーズ(ZUMZ.US)$– Zumiez beat estimates by 23 cents with adjusted quarterly earnings of $1.02 per share, but revenue fell short of the consensus view. The maker of streetwear and action sports apparel did not provide an outlook, due to volatile market conditions, and shares fell 5.3% in premarket trading.
ズミーズに関するコメント
5 hot insider trades & hedge fund hits: Cathie Wood snaps up more Coinbase
Cathie Wood's Ark Invest boosted its holdings in $コインベース(COIN.US)$ amidst a crypto industry crackdown by the SEC, driving the stock to nearly five-month lows. Data from Cathie's Ark revealed that three of Wood's funds purchased over 400,000 Coinbase shares, with her main $ARK Innovation ETF(ARKK.US)$ acquiring more than 300,000. This occurred as Coinbase's stock pri...
Gonna try and grab this falling knife and going long. Gonna buy tomorrow likely…..conditions depending.
コラムToday's Pre-Market Stock Movers: DOCU, ZS, DWAC, MARA and More
$ドキュサイン(DOCU.US)$ +16% (fiscal second-quarter earnings and revenue that topped Wall Street estimates and raised its forecast for fiscal-year billings.)
$ゼットスケーラー(ZS.US)$ +15% (the internet security platform issued a forecast better than Wall Street estimates.)
$テスラ(TSLA.US)$ +1.3% (The electric vehicle maker is considering building a lithium refinery for EV battery production in Texas this year, according to an applicati...
Very undervalued
コラムToday's pre-market stock movers: TSLA, CHGG, OKTA, TPTX and more
• $オクタ(OKTA.US)$ +15.8% (In reaction to earnings)
• $ストーン(STNE.US)$ +12.9% (In reaction to earnings)
• $ターニング・ポイント・セラピューティクス(TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $アミリックス・ファーマシューティカルズ(AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
まだコメントはありません